Please login to read the full article.
Scrip Regulatory Affairs
The IOM report on the 510(k) clearance process in the US: a starting point for debate
13 September 2011
Meaghan Bailey and Jack Kent
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Medtech companies urge US FDA to enhance, not replace, 510(k) process
- US FDA announces training programmes for device review staff
- US FDA plans September meeting to discuss IOM proposal to scrap 510(k)
- IOM report recommends abandoning US FDA 510(k) process in favour of new framework; industry concerned
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
